The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy

Paul Chan, Ching Bing Lee, Tz Shing Lin, Jiing Tang Ko, Wen Harn Pan, Ying Shiung Lee

研究成果: 雜誌貢獻文章

15 引文 (Scopus)

摘要

To evaluate the efficacy and safety of low dose (10 mg) pravastatin in hypercholesterolemic, hypertensive elderly subjects undergoing antihypertensive treatment, a randomized, double-blind, placebo-controlled 6-month trial was conducted. The subjects had a total plasma cholesterol of at least 250 mg/dL and had been, for at least 3 months, consuming a standard lipid-lowering diet (American Heart Association Step 1 Diet). Sixty elderly hypertensive patients randomly received placebo (n = 30) or pravastatin (n = 30) treatment. The dosage consisted of 10 mg of pravastatin daily during the 6-month trial. Over that period, in the pravastatin group, plasma levels of total cholesterol and LDLcholesterol significantly (P <.01) dropped (-20% and -25%, respectively) compared to the placebo group. The plasma level of HDL-cholesterol increased (+5%) while triglycerides slightly decreased (-8%) (P <.05). No serious side effects occurred, and pravastatin was generally tolerated. Fasting hyperinsulinemia (11.0 ± 0.8 v 9.3 ± 0.7 μU/mL; P = .06) also improved, although not significantly, after 6 months of pravastatin therapy. Results from this study confirmed that a low dose (10 mg) of pravastatin daily is a safe and effective method of reducing plasma total and LDL-cholesterol in hypercholesterolemic, hypertensive elderly patients who are on concurrent antihypertensive drug therapy.

原文英語
頁(從 - 到)1099-1104
頁數6
期刊American Journal of Hypertension
8
發行號11
DOIs
出版狀態已發佈 - 1995
對外發佈Yes

指紋

Pravastatin
Antihypertensive Agents
Safety
Placebos
Therapeutics
Cholesterol
Diet
Hyperinsulinism
LDL Cholesterol
HDL Cholesterol
Fasting
Triglycerides
Lipids
Drug Therapy

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

引用此文

The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy. / Chan, Paul; Lee, Ching Bing; Lin, Tz Shing; Ko, Jiing Tang; Pan, Wen Harn; Lee, Ying Shiung.

於: American Journal of Hypertension, 卷 8, 編號 11, 1995, p. 1099-1104.

研究成果: 雜誌貢獻文章

Chan, Paul ; Lee, Ching Bing ; Lin, Tz Shing ; Ko, Jiing Tang ; Pan, Wen Harn ; Lee, Ying Shiung. / The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy. 於: American Journal of Hypertension. 1995 ; 卷 8, 編號 11. 頁 1099-1104.
@article{73e883e900e5485381724dd53ba46295,
title = "The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy",
abstract = "To evaluate the efficacy and safety of low dose (10 mg) pravastatin in hypercholesterolemic, hypertensive elderly subjects undergoing antihypertensive treatment, a randomized, double-blind, placebo-controlled 6-month trial was conducted. The subjects had a total plasma cholesterol of at least 250 mg/dL and had been, for at least 3 months, consuming a standard lipid-lowering diet (American Heart Association Step 1 Diet). Sixty elderly hypertensive patients randomly received placebo (n = 30) or pravastatin (n = 30) treatment. The dosage consisted of 10 mg of pravastatin daily during the 6-month trial. Over that period, in the pravastatin group, plasma levels of total cholesterol and LDLcholesterol significantly (P <.01) dropped (-20{\%} and -25{\%}, respectively) compared to the placebo group. The plasma level of HDL-cholesterol increased (+5{\%}) while triglycerides slightly decreased (-8{\%}) (P <.05). No serious side effects occurred, and pravastatin was generally tolerated. Fasting hyperinsulinemia (11.0 ± 0.8 v 9.3 ± 0.7 μU/mL; P = .06) also improved, although not significantly, after 6 months of pravastatin therapy. Results from this study confirmed that a low dose (10 mg) of pravastatin daily is a safe and effective method of reducing plasma total and LDL-cholesterol in hypercholesterolemic, hypertensive elderly patients who are on concurrent antihypertensive drug therapy.",
keywords = "Cholesterol, hypercholesterolemia, hypertension, pravastatin",
author = "Paul Chan and Lee, {Ching Bing} and Lin, {Tz Shing} and Ko, {Jiing Tang} and Pan, {Wen Harn} and Lee, {Ying Shiung}",
year = "1995",
doi = "10.1016/0895-7061(95)00229-I",
language = "English",
volume = "8",
pages = "1099--1104",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - The effectiveness and safety of low dose pravastatin in elderly hypertensive hypercholesterolemic subjects on antihypertensive therapy

AU - Chan, Paul

AU - Lee, Ching Bing

AU - Lin, Tz Shing

AU - Ko, Jiing Tang

AU - Pan, Wen Harn

AU - Lee, Ying Shiung

PY - 1995

Y1 - 1995

N2 - To evaluate the efficacy and safety of low dose (10 mg) pravastatin in hypercholesterolemic, hypertensive elderly subjects undergoing antihypertensive treatment, a randomized, double-blind, placebo-controlled 6-month trial was conducted. The subjects had a total plasma cholesterol of at least 250 mg/dL and had been, for at least 3 months, consuming a standard lipid-lowering diet (American Heart Association Step 1 Diet). Sixty elderly hypertensive patients randomly received placebo (n = 30) or pravastatin (n = 30) treatment. The dosage consisted of 10 mg of pravastatin daily during the 6-month trial. Over that period, in the pravastatin group, plasma levels of total cholesterol and LDLcholesterol significantly (P <.01) dropped (-20% and -25%, respectively) compared to the placebo group. The plasma level of HDL-cholesterol increased (+5%) while triglycerides slightly decreased (-8%) (P <.05). No serious side effects occurred, and pravastatin was generally tolerated. Fasting hyperinsulinemia (11.0 ± 0.8 v 9.3 ± 0.7 μU/mL; P = .06) also improved, although not significantly, after 6 months of pravastatin therapy. Results from this study confirmed that a low dose (10 mg) of pravastatin daily is a safe and effective method of reducing plasma total and LDL-cholesterol in hypercholesterolemic, hypertensive elderly patients who are on concurrent antihypertensive drug therapy.

AB - To evaluate the efficacy and safety of low dose (10 mg) pravastatin in hypercholesterolemic, hypertensive elderly subjects undergoing antihypertensive treatment, a randomized, double-blind, placebo-controlled 6-month trial was conducted. The subjects had a total plasma cholesterol of at least 250 mg/dL and had been, for at least 3 months, consuming a standard lipid-lowering diet (American Heart Association Step 1 Diet). Sixty elderly hypertensive patients randomly received placebo (n = 30) or pravastatin (n = 30) treatment. The dosage consisted of 10 mg of pravastatin daily during the 6-month trial. Over that period, in the pravastatin group, plasma levels of total cholesterol and LDLcholesterol significantly (P <.01) dropped (-20% and -25%, respectively) compared to the placebo group. The plasma level of HDL-cholesterol increased (+5%) while triglycerides slightly decreased (-8%) (P <.05). No serious side effects occurred, and pravastatin was generally tolerated. Fasting hyperinsulinemia (11.0 ± 0.8 v 9.3 ± 0.7 μU/mL; P = .06) also improved, although not significantly, after 6 months of pravastatin therapy. Results from this study confirmed that a low dose (10 mg) of pravastatin daily is a safe and effective method of reducing plasma total and LDL-cholesterol in hypercholesterolemic, hypertensive elderly patients who are on concurrent antihypertensive drug therapy.

KW - Cholesterol

KW - hypercholesterolemia

KW - hypertension

KW - pravastatin

UR - http://www.scopus.com/inward/record.url?scp=0028880638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028880638&partnerID=8YFLogxK

U2 - 10.1016/0895-7061(95)00229-I

DO - 10.1016/0895-7061(95)00229-I

M3 - Article

C2 - 8554733

AN - SCOPUS:0028880638

VL - 8

SP - 1099

EP - 1104

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 11

ER -